Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)
Irene J Higginson(King's College London), Sarah Brown(University of Leeds), David C. Currow(Flinders University), Simon P. Hart(University of Hull), Andrew Wilcock(Providence College), Vincent Crosby(Nottingham University Hospitals NHS Trust), Heather Poad(University of Leeds), Deokhee Yi(King's College London), Miriam J. Johnson(University of Hull), Sabrina Bajwah(King's College London), Emma L. Best(University of Leeds), Natasha Lovell(King's College London)
Cited by 26
Related Papers
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
|The Lancet Oncology|2019|1k
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
|The Lancet|2015|477
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
|The Lancet Oncology|2013|392
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2019|343